Advik Laboratories gains on planning to raise funds via various modes
Advik Laboratories is currently trading at its upper circuit limit of Rs. 1.45, up by 0.06 points or 4.32% from its previous closing of Rs. 1.39 on the BSE.
The scrip opened at Rs. 1.45 and has touched a high and low of Rs. 1.45 and Rs. 1.45 respectively. So far 3148 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1.45 on 11-Apr-2022 and a 52 week low of Rs. 0.89 on 09-Apr-2021.
The promoters holding in the company stood at 35.89% and Non-Institutions held 64.11%.
Advik Laboratories is planning to raise funds by way of issue of one or more instruments including equity shares/ convertible securities or warrants on preferential basis at such price as may be determined in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to such approvals as may be required. A meeting of Board of Directors of the Company is scheduled to be held on April 15, 2022 to approve the same.
Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.
